Anne Dejean's Group (»Add to Infobox)

General description: The group is centered on the study of molecular and cellular mechanisms leading to human cancers with a particular emphasis on the role of certain post-translational modifications. To this end, two distinct but complementary approaches are taken: a first, or 'global' approach seeks to establish a general profile of genetic and epigenetic alterations associated with the development of hepatocellular carcinoma, whereas the second, more 'mechanistic' approach centers on the role of the SUMO pathway in both development and oncogenesis. The sum of these projects is anticipated to provide a further basis for the development of cancer therapeutic strategies that target or modulate these post-translational modification systems. Role in RUBICON: Our work will focus on protein modification by SUMO, known to play critical roles in numerous fundamental cellular processes. The identification of novel components of this pathway, particularly of E3 ligases and associated cofactors represents a primary objective. Further, the role of the SUMO pathway in oncogenic transformation, cellular senescence and in the maintenance of genomic integrity will be studied in cell (mammalian and yeast) as well as animal (mouse) model systems. To this end, we generated mouse lines in which sumoylation has been conditionally inactivated (null allele) or reduced (hypomorphic allele).

MEMBERS (11/11)

Dejean Anne (Principal Investigator / Anne Dejean's Group)